OncoSec Receives $7 Million Investment From Alpha Holdings At $1.50 Per Share Dec 10, 2018 8:30am EST
OncoSec Presents New Data During Oral Presentation At Melanoma Bridge Demonstrating Intratumoral Monotherapy TAVO™ Induces Abscopal Responses In Metastatic Melanoma Patients Nov 29, 2018 8:00am EST
OncoSec To Present Data in Late-Stage Triple Negative Breast Cancer (TNBC) at the 2018 San Antonio Breast Cancer Symposium® Nov 13, 2018 8:00am EST
OncoSec Reports Preliminary Data from KEYNOTE-695 Phase 2b Registration-Directed Clinical Trial of TAVO™ in Combination with KEYTRUDA® for Metastatic Melanoma at Society for Immunotherapy of Cancer's 33rd Annual Meeting Nov 06, 2018 8:00am EST
OncoSec Announces Preliminary Data from KEYNOTE-695 Study Accepted for Late-Breaking Presentation at SITC Annual Meeting Nov 02, 2018 8:00am EDT
